Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Shares (2023)

PharmaCyte Biotech (PMCB) has disclosed Preferred Shares for 4 consecutive years, with $20.0 million as the latest value for Q3 2023.

  • Quarterly Preferred Shares changed N/A to $20.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Jul 2023, changed N/A year-over-year, with the annual reading at $580000.0 for FY2013, 0.0% changed from the prior year.
  • Preferred Shares for Q3 2023 was $20.0 million at PharmaCyte Biotech, up from $500000.0 in the prior quarter.
  • The five-year high for Preferred Shares was $20.0 million in Q3 2023, with the low at $20.0 million in Q3 2023.